2000—2024年神经系统疾病与肠道菌群关系研究变化情况的可视化分析

doi:10.12114/j.issn.1007-9572.2024.0720

中国全科医学 ›› 2026, Vol. 29 ›› Issue (09): 1168-1179.DOI: 10.12114/j.issn.1007-9572.2024.0720

• 论著 • 上一篇

2000—2024年神经系统疾病与肠道菌群关系研究变化情况的可视化分析

郭阳阳¹, 张琳琳², 石广志¹, 张晋东³^,^*()

1．100070　北京市，首都医科大学附属北京天坛医院重症医学科
2．100029　北京市，首都医科大学附属北京安贞医院神经重症监护室
3．100191　北京市，北京大学第三医院消化科

收稿日期:2025-04-10 修回日期:2025-07-16 出版日期:2026-03-20 发布日期:2026-01-28
通讯作者: 张晋东
作者贡献：
郭阳阳负责文献数据分析，图表制作，论文的质量控制及核查，论文撰写及修改，并对论文整体负责；张琳琳负责文献检索，筛选和去重；石广志负责论文数据核验，论文质量控制及修改；张晋东负责确定论文选题，论文修改，论文结构总体把控，确定终稿，并对论文整体负责。
基金资助:
国家自然科学基金资助项目(82000510)

A Bibliometric and Visualized Analysis of Research Trends in the Relationship between Neurological Disorders and Gut Microbiota from 2000 to 2024

GUO Yangyang¹, ZHANG Linlin², SHI Guangzhi¹, ZHANG Jindong³^,^*()

1. Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China
2. Department of Neurocritical Care, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
3. Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China

Received:2025-04-10 Revised:2025-07-16 Published:2026-03-20 Online:2026-01-28
Contact: ZHANG Jindong

分享到

摘要/Abstract

摘要： 背景神经系统疾病严重影响患者生活质量，其复杂病因涉及遗传、感染、免疫等多种因素。近年来，关于肠道微生物群通过肠-脑轴参与神经系统疾病发生、发展的研究引起了广泛关注，但相关研究热点和发展趋势尚未得到系统梳理。目的对神经系统疾病与肠道菌群相关文献进行可视化分析，以了解国内外研究的现状，探索其热点和前沿趋势，为未来的研究提供参考依据。方法检索Web of Science数据库核心合集中自2000-01-01—2024-07-29的相关文献，运用CiteSpace软件从发文量、文献共被引、高被引文献、引文激增文献、关键词共现、国家合作、机构合作及作者合作等多个方面进行可视化分析。结果共纳入5 239篇文献，自2012年以来，发文量逐年上升，2022年年发文量超过1 000篇。研究热点主要集中于帕金森病、阿尔茨海默病、缺血性卒中及肌萎缩侧索硬化症等领域。文献共被引分析显示，肠道菌群与神经系统疾病的关系正成为近年来的研究重点。关键词共现分析进一步明确了短链脂肪酸、肠-脑轴、肠道菌群失调等重要研究主题的频繁出现，反映了对这些方向的高度关注。高被引文章和引文激增文献分析显示，研究趋势主要集中在肠道微生物对神经退行性疾病及中枢神经系统其他疾病的影响机制上，尤其是短链脂肪酸、肠道菌群多样性和肠-脑轴的调控作用。结论基于CiteSpace的文献计量学分析可见肠道菌群与多种神经系统疾病（如帕金森病、阿尔茨海默病、多发性硬化症等）之间的潜在关联，通过干预微生物群失调有望为神经系统疾病的治疗开辟新的方向。进一步的纵向研究和临床试验将有助于验证这一观点，揭示肠道菌群在神经系统疾病中的作用机制。

关键词: 神经系统疾病, 肠道菌群, CiteSpace, 文献计量学, 可视化分析

Abstract:

Background

Neurological disorders severely impact patients' quality of life. These disorders have multifactorial etiologies, including genetic, infectious, and immunological factors. Emerging evidence highlights the role of gut microbiota in these disorders through the gut-brain axis. However, the research hotspots and trends in this field remain inadequately characterized.

Objective

This study aims to conduct a visual analysis of the literature related to neurological disorders and gut microbiota, with the goal of understanding the current research landscape both domestically and internationally. Furthermore, it seeks to explore the research hotspots and emerging trends, thereby providing a reference for future studies.

Methods

Relevant literature was retrieved from the Web of Science Core Collection database from January 1, 2000 to July 29, 2024. Using CiteSpace software, a visual analysis was performed from multiple aspects, including publication volume, co-citation analysis, highly cited papers, citation burst papers, keyword co-occurrence, national collaboration, institutional collaboration, and author collaboration.

Results

A total of 5 239 articles were included, with a steady increase in publication volume since 2012, surpassing 1 000 articles in 2022. The research hotspots primarily concentrated on Parkinson's disease, Alzheimer's disease, ischemic stroke, and amyotrophic lateral sclerosis. Citation analysis revealed that the relationship between gut microbiota and CNS diseases had become a prominent research focus in recent years. Moreover, co-occurrence analysis of keywords further highlighted the frequent appearance of important research topics such as short-chain fatty acids, the gut-brain axis, and gut microbiota dysbiosis, indicating a high level of attention to these areas. High-citation articles and citation burst analysis showed that the research trend was centered on the mechanisms through which gut microbiota influence neurodegenerative diseases and other CNS disorders, particularly focusing on the regulatory roles of short-chain fatty acids, gut microbiota diversity, and the gut-brain axis.

Conclusion

CiteSpace-based bibliometric analysis suggests a potential association between gut microbiota and neurological disorders such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Modulation of gut microbiota may offer a promising therapeutic avenue for the management of these conditions. Further longitudinal studies and clinical trials are warranted to validate this hypothesis and to elucidate the underlying mechanisms by which the gut microbiota influences neurological disease pathogenesis.

Key words: Nervous system diseases, Gut microbiota, CiteSpace, Bibliometric, Visual analysis

中图分类号:

R 74

郭阳阳,张琳琳,石广志,等. 2000—2024年神经系统疾病与肠道菌群关系研究变化情况的可视化分析[J]. 中国全科医学, 2026, 29(09): 1168-1179. DOI: 10.12114/j.issn.1007-9572.2024.0720.
GUO Yangyang,ZHANG Linlin,SHI Guangzhi, et al. A Bibliometric and Visualized Analysis of Research Trends in the Relationship between Neurological Disorders and Gut Microbiota from 2000 to 2024[J]. Chinese General Practice, 2026, 29(09): 1168-1179. DOI: 10.12114/j.issn.1007-9572.2024.0720.

图/表 13

图1 2000—2024年肠道菌群领域相关文献发文趋势

Figure 1 Publication trends in gut microbiota research in 2000-2024

图2 2000—2024年肠道菌群领域相关文献学科分布

Figure 2 Subject distribution of gut microbiota research publications in 2000-2024

图3 2000—2024年神经系统疾病与肠道菌群相关文献发文量及被引频次

Figure 3 Number of publications and citation frequency of research on neurological diseases and gut microbiota in 2000-2024

图4 神经系统疾病与肠道菌群领域相关文献共被引聚类网络图谱

Figure 4 Co-citation clustering network map of literature related to neurological diseases and gut microbiota

表1 2005—2024年神经系统疾病与肠道菌群领域共被引网络中16个最大聚类的信息总结

Table 1 Summary of information for the 16 largest clusters in the co-citation network of neurological diseases and gut microbiota in 2005-2024

聚类编号	聚类规模	轮廓值	发表年份（平均值）（年）	聚类标签（LLR）
0	187	0.962	2017	parkinsons disease
1	169	0.866	2013	depression
2	169	0.914	2018	alzheimers disease
3	112	0.946	2009	autoimmunity
4	93	0.910	2017	multiple sclerosis
5	82	0.976	2017	ischemic stroke
6	62	0.913	2011	obesity
7	58	0.993	2005	asthma
8	51	0.936	2017	epilepsy
9	49	0.958	2019	amyotrophic lateral sclerosis
10	24	0.969	2011	gut microbiota
12	16	0.983	2018	short-chain fatty acids
16	9	0.999	2017	akkermansia muciniphila
17	9	0.988	2013	preterm
18	8	0.990	2007	minerals
19	8	0.996	2013	immune signaling

图5 神经系统疾病与肠道菌群领域相关文献共被引聚类网络时间趋势图

Figure 5 Temporal trend of the co-citation clustering network in the literature related to neurological diseases and gut microbiota

图6 神经系统疾病与肠道菌群领域高被引文章网络图谱

Figure 6 Network map of highly cited articles in the field of neurological diseases and gut microbiota

表2 2006—2024年神经系统疾病与肠道菌群领域引用频率最高的10篇文献相关情况

Table 2 Top 10 most cited articles in the field of neurological diseases and gut microbiota from 2006 to 2024

引用次数（次）	第一作者	共被引文献节点标识	DOI
898	SAMPSON^[21]	P1469	10.1016/j.cell.2016.11.018
670	VOGT^[32]	P0	10.1038/s41598-017-13601-y
645	ERNY^[30]	P965	10.1038/nn.4030
625	SCHEPERJANS^[27]	P350	10.1002/mds.26069
537	CRYAN^[33]	P1877	10.1152/physrev.00018.2018
484	CATTANEO^[22]	P60	10.1016/j.neurobiolaging.2016.08.019
479	UNGER^[28]	P66	10.1016/j.parkreldis.2016.08.019
474	KESHAVARZIAN^[29]	P1351	10.1002/mds.26307
399	JANGI^[4]	P0	10.1038/ncomms12015
371	BRANISTE^[31]	P0	10.1126/scitranslmed.3009759

表3 2022—2024年神经系统疾病与肠道菌群领域引用激增的文献

Table 3 Literature with citation surge in the field of neurological diseases and gut microbiota from 2022 to 2024

第一作者	发表年份（年）	引用强度
ROMANO^[2]	2021	17.806 1
AHO^[34]	2021	17.779 6
RUTSCH^[41]	2020	17.608 3
KESIKA^[3]	2021	16.923 1
COLOMBO^[36]	2021	14.012 3
TAN^[1]	2021	12.472 1
XU^[40]	2021	12.130 0
LING^[37]	2020	11.445 7
MARIZZONI^[38]	2020	11.159 7
NEEDHAM^[42]	2020	11.103 6
SRIVASTAV^[35]	2019	10.590 5
DEN^[39]	2020	10.299 0

图7 神经系统疾病与肠道菌群领域文献关键词共现网络图谱

Figure 7 Co-occurrence network map of keywords in the field of neurological diseases and gut microbiota

图8 神经系统疾病与肠道菌群领域文献不同国家/地区合作网络图谱

Figure 8 Collaboration network map of different countries/regions in the field of neurological diseases and gut microbiota

图9 神经系统疾病与肠道菌群领域文献不同机构合作网络图谱

Figure 9 Collaboration network map of different institutions in the field of neurological diseases and gut microbiota

图10 神经系统疾病与肠道菌群领域文献作者合作网络图谱

Figure 10 Author collaboration network map in the field of neurological diseases and gut microbiota

参考文献 54

[1]	TAN C H, WU Q H, WANG H D, et al. Dysbiosis of gut microbiota and short-chain fatty acids in acute ischemic stroke and the subsequent risk for poor functional outcomes[J]. JPEN J Parenter Enteral Nutr, 2021, 45(3): 518-529. DOI: 10.1002/jpen.1861.
[2]	ROMANO S, SAVVA G M, BEDARF J R, et al. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation[J]. NPJ Parkinsons Dis, 2021, 7(1): 27. DOI: 10.1038/s41531-021-00156-z.
[3]	KESIKA P, SUGANTHY N, SIVAMARUTHI B S, et al. Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease[J]. Life Sci, 2021, 264: 118627. DOI: 10.1016/j.lfs.2020.118627.
[4]	JANGI S, GANDHI R, COX L M, et al. Alterations of the human gut microbiome in multiple sclerosis[J]. Nat Commun, 2016, 7: 12015. DOI: 10.1038/ncomms12015.
[5]	YUE Q, CAI M F, XIAO B, et al. The microbiota-gut-brain axis and epilepsy[J]. Cell Mol Neurobiol, 2022, 42(2): 439-453. DOI: 10.1007/s10571-021-01130-2.
[6]	WANG Q W, YANG Q Y, LIU X Y. The microbiota-gut-brain axis and neurodevelopmental disorders[J]. Protein Cell, 2023, 14(10): 762-775. DOI: 10.1093/procel/pwad026.
[7]	CRYAN J F, DINAN T G. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour[J]. Nat Rev Neurosci, 2012, 13(10): 701-712. DOI: 10.1038/nrn3346.
[8]	TILLISCH K, LABUS J, KILPATRICK L, et al. Consumption of fermented milk product with probiotic modulates brain activity[J]. Gastroenterology, 2013, 144(7): 1394-1401, 1401.e1-1401.e4. DOI: 10.1053/j.gastro.2013.02.043.
[9]	DIAZ HEIJTZ R, WANG S, ANUAR F, et al. Normal gut microbiota modulates brain development and behavior[J]. Proc Natl Acad Sci USA, 2011, 108(7): 3047-3052. DOI: 10.1073/pnas.1010529108.
[10]	FORSYTHE P, KUNZE W A. Voices from within: gut microbes and the CNS[J]. Cell Mol Life Sci, 2013, 70(1): 55-69. DOI: 10.1007/s00018-012-1028-z.
[11]	BERCIK P, DENOU E, COLLINS J, et al. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice[J]. Gastroenterology, 2011, 141(2): 599-609, 609.e1-609.e3. DOI: 10.1053/j.gastro.2011.04.052.
[12]	FUNG T C, OLSON C A, HSIAO E Y. Interactions between the microbiota, immune and nervous systems in health and disease[J]. Nat Neurosci, 2017, 20(2): 145-155. DOI: 10.1038/nn.4476.
[13]	MAYER E A, NANCE K, CHEN S. The gut-brain axis[J]. Annu Rev Med, 2022, 73: 439-453. DOI: 10.1146/annurev-med-042320-014032.
[14]	LOH J S, MAK W Q, TAN L K S, et al. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases[J]. Signal Transduct Target Ther, 2024, 9(1): 37. DOI: 10.1038/s41392-024-01743-1.
[15]	AGIRMAN G, YU K B, HSIAO E Y. Signaling inflammation across the gut-brain axis[J]. Science, 2021, 374(6571): 1087-1092. DOI: 10.1126/science.abi6087.
[16]	SELKRIG J, WONG P, ZHANG X D, et al. Metabolic tinkering by the gut microbiome: implications for brain development and function[J]. Gut Microbes, 2014, 5(3): 369-380. DOI: 10.4161/gmic.28681.
[17]	SCHNEIDER S, WRIGHT C M, HEUCKEROTH R O. Unexpected roles for the second brain: enteric nervous system as master regulator of bowel function[J]. Annu Rev Physiol, 2019, 81: 235-259. DOI: 10.1146/annurev-physiol-021317-121515.
[18]	DOGRA N, MANI R J, KATARE D P. The gut-brain axis: two ways signaling in Parkinson's disease[J]. Cell Mol Neurobiol, 2022, 42(2): 315-332. DOI: 10.1007/s10571-021-01066-7.
[19]	ZHENG Y D, BONFILI L, WEI T, et al. Understanding the gut-brain axis and its therapeutic implications for neurodegenerative disorders[J]. Nutrients, 2023, 15(21): 4631. DOI: 10.3390/nu15214631.
[20]	O'RIORDAN K J, COLLINS M K, MOLONEY G M, et al. Short chain fatty acids: microbial metabolites for gut-brain axis signalling[J]. Mol Cell Endocrinol, 2022, 546: 111572. DOI: 10.1016/j.mce.2022.111572.
[21]	SAMPSON T R, DEBELIUS J W, THRON T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease[J]. Cell, 2016, 167(6): 1469-1480.e12. DOI: 10.1016/j.cell.2016.11.018.
[22]	CATTANEO A, CATTANE N, GALLUZZI S, et al. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly[J]. Neurobiol Aging, 2017, 49: 60-68. DOI: 10.1016/j.neurobiolaging.2016.08.019.
[23]	CHEN C M. Science mapping: a systematic review of the literature[J]. J Data Inf Sci, 2017, 2(2): 1-40. DOI: 10.1515/jdis-2017-0006.
[24]	CHEN C M. CiteSpaceⅡ: Detecting and visualizing emerging trends and transient patterns in scientific literature[J]. J Am Soc Inf Sci Technol, 2006, 57(3): 359-377. DOI: 10.1002/asi.20317.
[25]	CHEN C M. Searching for intellectual turning points: progressive knowledge domain visualization[J]. Proc Natl Acad Sci USA, 2004, 101(Suppl 1): 5303-5310. DOI: 10.1073/pnas.0307513100.
[26]	陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253. DOI: 10.16192/j.cnki.1003-2053.2015.02.009.
[27]	SCHEPERJANS F, AHO V, PEREIRA PA, KOSKINEN K, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype[J]. Mov Disord, 2015, 30(3): 350-358. DOI: 10.1002/mds.26069.
[28]	UNGER M M, SPIEGEL J, DILLMANN K U, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls[J]. Parkinsonism Relat Disord, 2016, 32: 66-72. DOI: 10.1016/j.parkreldis.2016.08.019.
[29]	KESHAVARZIAN A, GREEN S J, ENGEN P A, et al. Colonic bacterial composition in Parkinson's disease[J]. Movement disorders 2015, 30(10): 1351-1360. DOI: 10.1002/mds.26307.
[30]	ERNY D, HRABĚ DE ANGELIS A L, JAITIN D, et al. Host microbiota constantly control maturation and function of microglia in the CNS[J]. Nat Neurosci, 2015, 18(7): 965-977. DOI: 10.1038/nn.4030.
[31]	BRANISTE V, AL-ASMAKH M, KOWAL C, et al. The gut microbiota influences blood-brain barrier permeability in mice[J]. Sci Transl Med, 2014, 6(263): 263ra158. DOI: 10.1126/scitranslmed.3009759.
[32]	VOGT N M, KERBY R L, DILL-MCFARLAND K A, et al. Gut microbiome alterations in Alzheimer's disease[J]. Sci Rep, 2017, 7(1): 13537. DOI: 10.1038/s41598-017-13601-y.
[33]	CRYAN J F, O'RIORDAN K J, COWAN C S M, et al. The microbiota-gut-brain axis[J]. Physiol Rev, 2019, 99(4): 1877-2013. DOI: 10.1152/physrev.00018.2018.
[34]	AHO V T E, HOUSER M C, PEREIRA P A B, et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease[J]. Mol Neurodegener, 2021, 16(1): 6. DOI: 10.1186/s13024-021-00427-6.
[35]	SRIVASTAV S, NEUPANE S, BHURTEL S, et al. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity[J]. J Nutr Biochem, 2019, 69: 73-86. DOI: 10.1016/j.jnutbio.2019.03.021.
[36]	COLOMBO A V, SADLER R K, LLOVERA G, et al. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition[J]. eLife, 2021, 10: e59826. DOI: 10.7554/eLife.59826.
[37]	LING Z, ZHU M, YAN X, et al. Structural and functional dysbiosis of fecal microbiota in Chinese patients with Alzheimer's disease[J]. Front Cell Dev Biol, 2020, 8: 634069. DOI: 10.3389/fcell.2020.634069.
[38]	MARIZZONI M, CATTANEO A, MIRABELLI P, et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer's disease[J]. J Alzheimers Dis, 2020, 78(2): 683-697. DOI: 10.3233/JAD-200306.
[39]	DEN H, DONG X H, CHEN M L, et al. Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer's disease or mild cognitive impairment-a meta-analysis of randomized controlled trials[J]. Aging, 2020, 12(4): 4010-4039. DOI: 10.18632/aging.102810.
[40]	XU K Y, GAO X X, XIA G H, et al. Rapid gut dysbiosis induced by stroke exacerbates brain infarction in turn[J]. Gut, 2021: gutjnl-2020-323263. DOI: 10.1136/gutjnl-2020-323263.
[41]	RUTSCH A, KANTSJÖ JB, RONCHI F. The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology[J]. Front Immunol, 2020, 11: 604179. DOI: 10.3389/fimmu.2020.604179.
[42]	NEEDHAM BD, KADDURAH-DAOUK R, MAZMANIAN SK. Gut microbial molecules in behavioural and neurodegenerative conditions[J]. Nat Rev Neurosci, 2020, 21(12): 717-731. DOI: 10.1038/s41583-020-00381-0.
[43]	JIA L H, KE Y Z, ZHAO S, et al. Metagenomic analysis characterizes stage-specific gut microbiota in Alzheimer's disease[J]. Mol Psychiatry, 2025. DOI: 10.1038/s41380-025-02973-7.
[44]	ZHA X, LIU X C, WEI M P, et al. Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's disease pathology via suppressing ferroptosis[J]. Cell Metab, 2025, 37(1): 169-186.e9. DOI: 10.1016/j.cmet.2024.10.006.
[45]	CHILTON P M, GHARE S S, CHARPENTIER B T, et al. Age-associated temporal decline in butyrate-producing bacteria plays a key pathogenic role in the onset and progression of neuropathology and memory deficits in 3 × Tg-AD mice[J]. Gut Microbes, 2024, 16(1): 2389319. DOI: 10.1080/19490976.2024.2389319.
[46]	ZHANG Y, HE X Q, QIAN Y W, et al. Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson's disease[J]. NPJ Parkinsons Dis, 2022, 8(1): 48. DOI: 10.1038/s41531-022-00312-z.
[47]	MSC Y Z, PHD Y L, SIRWAN K L DARWEESH MD P, et al. Gut microbial metabolites and future risk of Parkinson's disease: a metabolome-wide association study[J]. Mov Disord, 2025, 40(3): 556-560. DOI: 10.1002/mds.30054.
[48]	CHENG Y, TAN G H, ZHU Q H, et al. Efficacy of fecal microbiota transplantation in patients with Parkinson's disease: clinical trial results from a randomized, placebo-controlled design[J]. Gut Microbes, 2023, 15(2): 2284247. DOI: 10.1080/19490976.2023.2284247.
[49]	SCHEPERJANS F, LEVO R, BOSCH B, et al. Fecal microbiota transplantation for treatment of parkinson disease: a randomized clinical trial[J]. JAMA Neurol, 2024, 81(9): 925-938. DOI: 10.1001/jamaneurol.2024.2305.
[50]	LIU J M, LV X H, YE T, et al. Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson's disease: a bench-to-bedside translational approach[J]. Brain Behav Immun, 2024, 117: 270-282. DOI: 10.1016/j.bbi.2024.01.010.
[51]	MUNOZ-PINTO M F, CANDEIAS E, MELO-MARQUES I, et al. Gut-first Parkinson's disease is encoded by gut dysbiome[J]. Mol Neurodegener, 2024, 19(1): 78. DOI: 10.1186/s13024-024-00766-0.
[52]	ANTONINI CENCICCHIO M, MONTINI F, PALMIERI V, et al. Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity[J]. Cell Rep Med, 2025, 6(4): 102028. DOI: 10.1016/j.xcrm.2025.102028.
[53]	ZHANG W, DONG X Y, HUANG R. Gut microbiota in ischemic stroke: role of gut bacteria-derived metabolites[J]. Transl Stroke Res, 2023, 14(6): 811-828. DOI: 10.1007/s12975-022-01096-3.
[54]	ABURTO M R, CRYAN J F. Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota-gut-brain axis[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(4): 222-247. DOI: 10.1038/s41575-023-00890-0.

2000—2024年神经系统疾病与肠道菌群关系研究变化情况的可视化分析

A Bibliometric and Visualized Analysis of Research Trends in the Relationship between Neurological Disorders and Gut Microbiota from 2000 to 2024

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 13

参考文献 54

相关文章 15

编辑推荐

Metrics

留言

[1]	宋超, 许岩丽, 梁万年. 中国全科医学发展态势分析——基于《中国全科医学》2015—2024年研究型论文数据[J]. 中国全科医学, 2026, 29(04): 464-475.
[2]	田甜, 张飞, 张璇, 李铭麟, 王佳贺. 2013—2023年国内外全科医生培养的文献计量学研究[J]. 中国全科医学, 2026, 29(01): 50-57.
[3]	黄丹华, 官兰, 杨信, 张晓菲, 胡丙杰. 我国全科医学研究生学位论文的现状与分析[J]. 中国全科医学, 2025, 28(36): 4619-4626.
[4]	牛奔, 朱晓倩, 杨辰, 梁万年, 刘珏. 基于CiteSpace的国内外医疗大语言模型研究热点演进及趋势分析[J]. 中国全科医学, 2025, 28(25): 3200-3208.
[5]	徐乙莎, 李春梅, 王城城, 郭维, 甘雨浓, 张宇, 张文, 余葱葱. 慢性疲劳综合征不同年龄组人群肠道菌群特征分析[J]. 中国全科医学, 2025, 28(23): 2900-2907.
[6]	李丽清, 杨苏乐, 曾传美. 我国慢性病管理研究热点的演进路径与发展趋势预测研究[J]. 中国全科医学, 2025, 28(19): 2321-2329.
[7]	王松柱, 姚易, 周伊恒, 赵茄茜, 杨荣, 赵茜, 张瑞, 代华, 李东泽, 廖晓阳, 杨辉. 近五年全科医学研究热点及发展趋势分析：基于CiteSpace的可视化分析[J]. 中国全科医学, 2025, 28(19): 2330-2337.
[8]	戈琼, 胡佳康, 俞玉琪, 赖文文, 罗时文, 卢曲琴. RNA测序技术应用于肝癌的文献计量学分析[J]. 中国全科医学, 2025, 28(12): 1473-1478.
[9]	郭玉梦, 崔杨霖, 张宪忠. 基于孟德尔随机化探讨肠道菌群与失眠的因果关联研究[J]. 中国全科医学, 2025, 28(08): 954-961.
[10]	程琦, 于文兵, 李科科, 左右, 焦乾鑫, 刘新浩, 高丽丽. 基于CiteSpace的中学生心理健康研究的热点与前沿趋势分析[J]. 中国全科医学, 2025, 28(07): 853-862.
[11]	王舒云, 梁夏, 李霞, 林琳, 冯启明, 黄照权. 中国县域医共体研究热点与前沿分析[J]. 中国全科医学, 2025, 28(01): 83-88.
[12]	黄凯, 张浥, 杨春, 杨玲. 肠道菌群与心力衰竭合并抑郁的研究进展[J]. 中国全科医学, 2024, 27(35): 4455-4461.
[13]	王健健, 卢珊, 张研, 潘杰. 门急诊服务敏感疾病的研究进展：基于CiteSpace的文献计量分析[J]. 中国全科医学, 2024, 27(34): 4248-4255.
[14]	李苗苗, 吴雪, 景城阳, 张乐, 赵晖, 廖星. 快速综述在医学研究领域应用现状的文献计量学分析[J]. 中国全科医学, 2024, 27(33): 4215-4224.
[15]	罗宇, 罗丹, 唐彬秩. 肠道菌群：儿童肥胖的重要参与者[J]. 中国全科医学, 2024, 27(33): 4182-4189.